Merck-partnered antibody maker readies $300M IPO as HKEX picks up pace
Three weeks after InnoCare launched its IPO into the welcoming embrace of HKEX investors, Akesobio is looking to one-up the company with its own …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
